Study: NCT00001832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gp100:209-217 (210M)
Description: gp100 = gp100:209-217(210M) peptide - 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus gp100:209-217(210M) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.~MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51
Description: MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 125,000 IU/kg dose intravenous for 5 days for 6 weeks with 2 days rest per week.~720,000 IU/kg intravenous every 8 hours for a maximum of 12 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 125,000 IU/kg dose intravenous for 5 days for 6 weeks with 2 days rest per week.~720,000 IU/kg intravenous every 8 hours for a maximum of 12 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 125,000 IU/kg dose intravenous for 5 days for 6 weeks with 2 days rest per week.~720,000 IU/kg intravenous every 8 hours for a maximum of 12 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 125,000 IU/kg dose intravenous for 5 days for 6 weeks with 2 days rest per week.~720,000 IU/kg intravenous every 8 hours for a maximum of 12 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 125,000 IU/kg dose intravenous for 5 days for 6 weeks with 2 days rest per week.~720,000 IU/kg intravenous every 8 hours for a maximum of 12 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 125,000 IU/kg dose intravenous for 5 days for 6 weeks with 2 days rest per week.~720,000 IU/kg intravenous every 8 hours for a maximum of 12 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 125,000 IU/kg dose intravenous for 5 days for 6 weeks with 2 days rest per week.~720,000 IU/kg intravenous every 8 hours for a maximum of 12 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 125,000 IU/kg dose intravenous for 5 days for 6 weeks with 2 days rest per week.~720,000 IU/kg intravenous every 8 hours for a maximum of 12 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 125,000 IU/kg dose intravenous for 5 days for 6 weeks with 2 days rest per week.~720,000 IU/kg intravenous every 8 hours for a maximum of 12 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 125,000 IU/kg dose intravenous for 5 days for 6 weeks with 2 days rest per week.~720,000 IU/kg intravenous every 8 hours for a maximum of 12 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MART-1:26-35(27L)
Description: MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MART-1:26-35(27L)
Description: MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MART-1:26-35(27L)
Description: MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abl cells
Description: Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days Abl cells IA = Lymphocytes 10\^9-10\^11 IA over 30 minutes on day 0, repeated in 14 to 21 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abl cells
Description: Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days Abl cells IA = Lymphocytes 10\^9-10\^11 IA over 30 minutes on day 0, repeated in 14 to 21 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abl cells
Description: Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days Abl cells IA = Lymphocytes 10\^9-10\^11 IA over 30 minutes on day 0, repeated in 14 to 21 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abl cells
Description: Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days Abl cells IA = Lymphocytes 10\^9-10\^11 IA over 30 minutes on day 0, repeated in 14 to 21 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abl cells
Description: Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days Abl cells IA = Lymphocytes 10\^9-10\^11 IA over 30 minutes on day 0, repeated in 14 to 21 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abl cells
Description: Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days Abl cells IA = Lymphocytes 10\^9-10\^11 IA over 30 minutes on day 0, repeated in 14 to 21 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abl cells
Description: Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days Abl cells IA = Lymphocytes 10\^9-10\^11 IA over 30 minutes on day 0, repeated in 14 to 21 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abl cells
Description: Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days Abl cells IA = Lymphocytes 10\^9-10\^11 IA over 30 minutes on day 0, repeated in 14 to 21 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abl cells
Description: Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days Abl cells IA = Lymphocytes 10\^9-10\^11 IA over 30 minutes on day 0, repeated in 14 to 21 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abl cells
Description: Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days Abl cells IA = Lymphocytes 10\^9-10\^11 IA over 30 minutes on day 0, repeated in 14 to 21 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abl cells
Description: Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days Abl cells IA = Lymphocytes 10\^9-10\^11 IA over 30 minutes on day 0, repeated in 14 to 21 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abl cells
Description: Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days Abl cells IA = Lymphocytes 10\^9-10\^11 IA over 30 minutes on day 0, repeated in 14 to 21 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abl cells
Description: Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days Abl cells IA = Lymphocytes 10\^9-10\^11 IA over 30 minutes on day 0, repeated in 14 to 21 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abl cells
Description: Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days Abl cells IA = Lymphocytes 10\^9-10\^11 IA over 30 minutes on day 0, repeated in 14 to 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 5x25 mg/m\^2 intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 5x25 mg/m\^2 intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 5x25 mg/m\^2 intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 5x25 mg/m\^2 intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 5x25 mg/m\^2 intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 5x25 mg/m\^2 intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 5x25 mg/m\^2 intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 5x25 mg/m\^2 intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 5x25 mg/m\^2 intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 5x25 mg/m\^2 intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 5x25 mg/m\^2 intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 5x25 mg/m\^2 intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 5x25 mg/m\^2 intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 5x25 mg/m\^2 intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2x30 mg/kg, 2x60 mg/kg intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2x30 mg/kg, 2x60 mg/kg intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2x30 mg/kg, 2x60 mg/kg intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2x30 mg/kg, 2x60 mg/kg intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2x30 mg/kg, 2x60 mg/kg intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2x30 mg/kg, 2x60 mg/kg intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2x30 mg/kg, 2x60 mg/kg intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2x30 mg/kg, 2x60 mg/kg intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2x30 mg/kg, 2x60 mg/kg intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2x30 mg/kg, 2x60 mg/kg intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2x30 mg/kg, 2x60 mg/kg intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2x30 mg/kg, 2x60 mg/kg intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2x30 mg/kg, 2x60 mg/kg intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2x30 mg/kg, 2x60 mg/kg intravenous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GCSF (Growth colony stimulating factor)
Description: Beginning on day 1 or 2, GCSF will be administered subcutaneously at a dose of 5mcg/kg/day (not to exceed 300 mcg/day. Filgrastim administration will continue daily until neutrophil count \> 1.0 x10\^9/L x 3 days or \> 5.0 x10\^9/L.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GCSF (Growth colony stimulating factor)
Description: Beginning on day 1 or 2, GCSF will be administered subcutaneously at a dose of 5mcg/kg/day (not to exceed 300 mcg/day. Filgrastim administration will continue daily until neutrophil count \> 1.0 x10\^9/L x 3 days or \> 5.0 x10\^9/L.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GCSF (Growth colony stimulating factor)
Description: Beginning on day 1 or 2, GCSF will be administered subcutaneously at a dose of 5mcg/kg/day (not to exceed 300 mcg/day. Filgrastim administration will continue daily until neutrophil count \> 1.0 x10\^9/L x 3 days or \> 5.0 x10\^9/L.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GCSF (Growth colony stimulating factor)
Description: Beginning on day 1 or 2, GCSF will be administered subcutaneously at a dose of 5mcg/kg/day (not to exceed 300 mcg/day. Filgrastim administration will continue daily until neutrophil count \> 1.0 x10\^9/L x 3 days or \> 5.0 x10\^9/L.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GCSF (Growth colony stimulating factor)
Description: Beginning on day 1 or 2, GCSF will be administered subcutaneously at a dose of 5mcg/kg/day (not to exceed 300 mcg/day. Filgrastim administration will continue daily until neutrophil count \> 1.0 x10\^9/L x 3 days or \> 5.0 x10\^9/L.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GCSF (Growth colony stimulating factor)
Description: Beginning on day 1 or 2, GCSF will be administered subcutaneously at a dose of 5mcg/kg/day (not to exceed 300 mcg/day. Filgrastim administration will continue daily until neutrophil count \> 1.0 x10\^9/L x 3 days or \> 5.0 x10\^9/L.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GCSF (Growth colony stimulating factor)
Description: Beginning on day 1 or 2, GCSF will be administered subcutaneously at a dose of 5mcg/kg/day (not to exceed 300 mcg/day. Filgrastim administration will continue daily until neutrophil count \> 1.0 x10\^9/L x 3 days or \> 5.0 x10\^9/L.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis